LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design.

Publication

Author(s):

Kitahata MM, Drozd DR, Crane HM, Van Rompaey SE, Althoff KN, Gange SJ, Klein MB, Lucas GM, Abraham AG, Lo Re V 3rd, McReynolds J, Lober WB, Mendes A, Modur SP, Jing Y, Morton EJ, Griffith MA, Freeman AM, Moore RD.

Pub Title:

Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design.

Pub Date:

Feb 19 2015

Journal:

Title: 
AIDS Research and Treatment
Link: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350581/

PubMed: 25789171
Pub PDF: PDF icon 25789171.pdf

Abstract
The burden of HIV disease has shifted from traditional AIDS-defining illnesses to serious non-AIDS-defining comorbid conditions. Research aimed at improving HIV-related comorbid disease outcomes requires well-defined, verified clinical endpoints. We developed methods to ascertain and verify end-stage renal disease (ESRD) and end-stage liver disease (ESLD) and validated screening algorithms within the largest HIV cohort collaboration in North America (NA-ACCORD). Individuals who screened positive among all participants in twelve cohorts enrolled between January 1996 and December 2009 underwent medical record review to verify incident ESRD or ESLD using standardized protocols. We randomly sampled 6% of contributing cohorts to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ESLD and ESRD screening algorithms in a validation subcohort. Among 43,433 patients screened for ESRD, 822 screened positive of which 620 met clinical criteria for ESRD. The algorithm had 100% sensitivity, 99% specificity, 82% PPV, and 100% NPV for ESRD. Among 41,463 patients screened for ESLD, 2,024 screened positive of which 645 met diagnostic criteria for ESLD. The algorithm had 100% sensitivity, 95% specificity, 27% PPV, and 100% NPV for ESLD. Our methods proved robust for ascertainment of ESRD and ESLD in persons infected with HIV.
 

The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Kitahata MM, Drozd DR, Crane HM, Van Rompaey SE, Althoff KN, Gange SJ, Klein MB, Lucas GM, Abraham AG, Lo Re V 3rd, McReynolds J, Lober WB, Mendes A, Modur SP, Jing Y, Morton EJ, Griffith MA, Freeman AM, Moore RD. Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design. AIDS Res Treat. 2015;2015:923194. doi: 10.1155/2015/923194. Epub 2015 Feb 19. PubMed PMID: 25789171; PubMed Central PMCID: PMC4350581.